Serrapeptase, technically called Serratio Peptidase, is a proteolytic enzymes, meaning that it dissolves or digests protein.
Serrapeptase was first found in silkworms, as it is this enzyme that silkworms use to dissolve their cocoons. It is now produced as a nutritional supplement through fermentation of plant-grown enzymes.
How does it work?
The reason that serrapeptase has such valuable therapeutic potential is that it dissolves only non-living tissue – tissues that can be a barrier to healing and optimal health.
This special enzyme also helps reduce swelling after injury and inhibits the release of chemical messengers that cause pain. Its unique properties have led to a number of studies investigating its therapeutic benefits.
There are five main health benefits associated with serrapeptase:
1. It is often used for its pain relieving benefits. Serrapeptase decreases pain by blocking the release of bradkinin and other ‘pain messengers’ from inflamed or damaged tissue (1). Because of this it is often used as an alternative to common non-steroidal anti-inflammatory (NSAID) painkillers such as aspirin and ibuprofen, and is especially favoured by those concerned about side effects of long term NSAID usage such as ulcers bleeding in the digestive tract.
2. Serrapeptase has been studied for its anti-inflammatory benefits (2). The supplement is believed to improve symptoms related to a whole host of inflammatory conditions including rheumatoid arthritis, migraine and others due to its anti-inflammatory effects.
3. The supplement is an effective mucolytic, meaning that it thins mucous. It shows promise as a treatment for those with chronic sinusitis (3). Ear, nose and throat problems also involve uncomfortable symptoms linked with increased mucous secretion. Serrapeptase has also been studied as a potential treatment for these conditions (4).
4. Serrapeptase also appears to play a role in healing injury. The supplement has been used to support post-operative recovery, as well as speeding recovery from sprains and other injuries. For example, in a group of patients undergoing knee surgery, those taking serrapeptase supplements showed a 50% reduction in swelling compared to controls (5).
Injured joints, ligaments or muscles are coated with fibrin which works to support the injured tissue while it regenerates. Sometimes excess fibrin can form unwanted scar tissue, inflammation and pain. This fibrin takes up valuable space in which living tissue should grow, reducing the motion of muscles and joints. Therefore by dissolving fibrin, serrapeptase offers potential to enhance recovery after injury.
5. Because of its ability to dissolve fibrin, serrapeptase has also been used to dissolve arterial plaque, fibrous blockages in clogged or hardened arteries. As serrapeptase only dissolves dead or damaged tissue, this could enable the dissolution of harmful atherosclerotic plaques without causing any harm to the inside of the arteries.
Studies of serrapeptase supplementation have found positive benefits with a dosage of around 10mg, taken after meals three times daily. No long-term studies of this supplement have yet been conducted, although studies to date suggest that supplementation for a period of 4 weeks seems safe (1,2).
Although preliminary research looks promising, many of the studies have been small or uncontrolled and much of the supporting evidence is anecdotal (6). Serrapeptase does appear to show promise as an agent for reducing pain and inflammation and support recovery.
Clearly more research is needed to determine the role and value of serrapeptase in medicine, though studies to date suggest it has some clinical potential.
References 1. Mazzone A et al (1990) Evaluation of Serratiapeptidase in acute or chronic inflammation of torhinolarygology pathology: a multi-centre, double-blind randomized trial versus placebo. J Int Med Res 18:379-88 2. Tachibana M, Mizukoshi O, Harada Y, et al (1984) A multi-centre, double-blind study of serrapeptase versus placebo in post-antrotomy buccal swelling. Pharmatherapeutica 3:526-30 3. Mizukoshi D et al (1982) A double-blind study of Danzen tablets in the treatment of chronic sinusitis. Igaku Ayumi 123:768-778 4. Mazzonie C et al (1990) Evaluation of serrapeptase in acute or chronic inflammation of otorhinolaryngology pathology: a multicentre, double-blind randomized trial versus placebo. J Int Med Res 18(5):379-388. 5. Esch VP et al (1989) Reduction of postoperative swelling. Objective measurement of swelling in upper ankle joint in treatment with serrapeptase – a prospective study (german) Fortschr Med 107(4):76-8 6. Bhagat S et al (2013) Serratiopeptidase: a systematic review of the existing evidence. Int J Surg 11(3):209-217